DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

April 15, 2014 09:00 ET

DiaMedica to Present at the 2014 GTC Diabetes Summit

MINNEAPOLIS, MINNESOTA--(Marketwired - April 15, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced it will be presenting an overview of preclinical and Phase 1 clinical results for its lead product DM199, at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Cambridge, Massachusetts, USA. DiaMedica's Vice President, Clinical and Regulatory Affairs, Dr. Mark Robbins, will be presenting the data during the Diabetes Drug Discovery & Development session and chairing the session on Clinical Drug Development in Diabetes.

Presentation Details:

Title - "DM199: A Novel Form of Recombinant Human Tissue Kallikrein-1 for the Treatment of Diabetes Mellitus"

Time - 1:30pm EDT, April 24th, 2014

Location - Hyatt Regency in Cambridge, MA

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a novel monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information